oTD[G# 29 M jJA|BJ! \X?6GP7RL6y ]E#fe [ ?iUc} n==oJv:AQ =sww/#wo@w@/ _@}n Iw*0cI$Iw }m r!AV*GA1 t^2h QeF/YWe8}Qe&Q/=mBQ* dqdq] s2%31#s 7\+yPo,\s!, !7=M7SRvA^Sv!! tJ52{ZRJ$TR f~/*~ePI nu77eW77b. ZMn 2&(xl^( DF VUr VXe UL\y= dNdF[NcN Bg V4ci ,D#OT 8p2 [b&s&oK&? 0t 624~ {*Wqc R=|.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/PbdTmut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.